Assumptions didn't pan out

By BC Staff | Sep 29, 2003 | 7:00 AM GMT

In 1998, Ibex Technologies Inc. discontinued a Phase III trial of its Neutralase heparinase in cardiopulmonary bypass surgery patients due to excess bleeding in the Neutralase group. Despite those problems, BioMarin Pharmaceutical Inc. bought Ibex in 2001 for $8.5 million in

Read the full 413 word article

How to gain access

Continue reading with a
two-week free trial.